1.亳州市人民医院药学部,安徽 亳州 236800
2.亳州市人民医院神经内科,安徽 亳州 236800
Received:01 January 2026,
Revised:2026-02-27,
Accepted:28 February 2026,
Published:30 March 2026
移动端阅览
梁海,张红,夏茹楠,等.老年缺血性脑卒中患者CYP2C19基因多态性对血小板功能、炎症细胞因子的影响及预后不良因素分析 [J].中国药房,2026,37(06):782-787.
LIANG Hai,ZHANG Hong,XIA Runan,et al.Influence of CYP2C19 gene polymorphism on platelet function and inflammatory cytokines and analysis of factors associated with poor prognosis in elderly patients with ischemic stroke[J].ZHONGGUO YAOFANG,2026,37(06):782-787.
梁海,张红,夏茹楠,等.老年缺血性脑卒中患者CYP2C19基因多态性对血小板功能、炎症细胞因子的影响及预后不良因素分析 [J].中国药房,2026,37(06):782-787. DOI: 10.6039/j.issn.1001-0408.2026.06.15.
LIANG Hai,ZHANG Hong,XIA Runan,et al.Influence of CYP2C19 gene polymorphism on platelet function and inflammatory cytokines and analysis of factors associated with poor prognosis in elderly patients with ischemic stroke[J].ZHONGGUO YAOFANG,2026,37(06):782-787. DOI: 10.6039/j.issn.1001-0408.2026.06.15.
目的
2
探讨老年缺血性脑卒中患者
CYP2C19
基因多态性对血小板功能、炎症细胞因子的影响,并分析造成患者预后不良的潜在因素。
方法
2
回顾性收集2024年6月至2025年6月我院收治的接受
CYP2C19
基因型检测并接受氯吡格雷抗血小板治疗的老年缺血性脑卒中患者的临床资料。比较不同代谢型患者治疗前后血小板功能指标和炎症细胞因子水平。依据治疗6个月后的预后情况,将患者分为预后不良组和预后良好组,对其一般资料、代谢型、血小板功能指标以及炎症细胞因子水平进行单因素分析,将
P
<0.05的变量和治疗前炎症细胞因子水平纳入多因素Logistic回归分析,筛选造成患者预后不良的独立危险因素;采用多元线性回归进一步分析代谢型与炎症细胞因子的关系。
结果
2
共纳入老年缺血性脑卒中患者448例;其中正常代谢型162例,中间代谢型218例,慢代谢型68例,未见快代谢型和超快代谢型。治疗后,正常代谢型组、中间代谢型组和慢代谢型组患者的血小板聚集率和P选择素、血小板活化复合物1、超敏C反应蛋白(hs-CRP)、白细胞介素1β(IL-1β)、IL-6、肿瘤坏死因子α(TNF-α)水平(慢代谢型患者的血小板聚集率和P选择素、血小板活化复合物1水平除外)均显著低于同组治疗前,且正常代谢型组上述指标水平均显著低于同期中间代谢型组、慢代谢型组,中间代谢型组血小板功能指标水平均显著低于同期慢代谢组(
P
<0.05)。单因素和多因素Logistic回归分析结果显示,合并高血压、合并糖尿病、代谢型为中间代谢型及慢代谢型是老年缺血性脑卒中患者预后不良的独立危险因素(
P
<0.05)。多元线性回归分析结果显示,中间代谢型和慢代谢型组治疗前的血清hs-CRP、IL-1β、IL-6、TNF-α水平均较正常代谢型组显著升高(
P
<0.05),且慢代谢型的炎症细胞因子水平升高幅度更大。
结论
2
CYP2C19
中间代谢型和慢代谢型老年缺血性脑卒中患者的血小板抑制效果较差,炎症细胞因子水平较正常代谢型高;
CYP2C19
基因多态性和合并高血压、糖尿病可作为预后不良的独立预测指标。
OBJECTIVE
2
To investigate the influence of
CYP2C19
gene polymorphism on platelet function and inflammatory cytokines in elderly patients with ischemic stroke, and to analyze potential factors associated with poor prognosis.
METHODS
2
A retrospective study was conducted on elderly patients with ischemic stroke admitted to our hospital from June 2024 to June 2025, wh
o underwent
CYP2C19
genotype testing and received antiplatelet therapy with clopidogrel. The levels of platelet function indicators and inflammatory cytokines before and after treatment were compared among patients with different metabolic phenotypes. Based on the prognosis at 6 months post-treatment, patients were divided into poor prognosis group and good prognosis group. Univariate analysis was performed on general data, metabolic phenotype, the levels of platelet function indicators and inflammatory cytokines. Variables with
P
<0.05 and the levels of inflammatory cytokines before treatment were included in a multivariate Logistic regression analysis to identify independent risk factors for poor prognosis. Multiple linear regression was used to further analyze the relationship between metabolic phenotypes and inflammatory cytokines.
RESULTS
2
A total of 448 elderly patients with ischemic stroke were included; among them, 162 cases were normal metabolic phenotype, 218 were intermediate metabolic phenotype, and 68 were poor metabolic phenotype. No rapid or ultrarapid metabolic phenotypes were observed. After treatment, platelet aggregation rate, the levels of P-selectin and platelet activated complex-1 (PAC-1), high-sensitivity C-reactive Protein (hs-CRP), interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) in the normal metabolic phenotype group, intermediate metabolic phenotype group, and poor metabolic phenotype group (except for platelet aggregation rate, and the levels of P-selectin and PAC-1 in the poor metabolic phenotype group) were significantly lower than those before treatment in the same group. Moreover, the above indicators in the normal metabolic phenotype group were significantly lower than those in the intermediate and poor metabolic phenotype groups at the corresponding time, and the levels of platelet function indicators in the intermediate metabolic phenotype group were significantly lower than those in the poor metabol
ic phenotype group at the corresponding time (
P
<0.05). Univariate and multivariate Logistic regression analyses showed that combined with hypertension, combined with diabetes mellitus, and intermediate or poor metabolic genotypes were independent risk factors for poor prognosis in elderly patients with ischemic stroke (
P
<0.05). Multiple linear regression analysis showed that serum levels of hs-CRP, IL-1β, IL-6 and TNF-α before treatment were significantly higher in patients with intermediate and poor metabolic genotypes compared to those with normal metabolic genotype (
P
<0.05), with a greater magnitude of increase in inflammatory cytokines observed in the patients with poor metabolic genotype.
CONCLUSIONS
2
The elderly ischemic stroke patients with
CYP2C19
intermediate and poor metabolic genotypes have poor inhibition effect on platelet and higher levels of inflammatory cytokines than normal metabolic genotype;
CYP2C19
gene polymorphism, and in combination with hypertension and diabetes, can be used as independent predictors of poor prognosis.
GBD 2021 Causes of Death Collaborators . Global, regional, and national burden of stroke and its risk factors, 1990-2021:a systematic analysis for the global burden of disease study 2021 [J ] . Lancet Neurol , 2024 , 23 ( 10 ): 973 - 1003 .
张娜 , 张冰莹 , 董玉书 , 等 . 1990至2021年中国老年缺血性脑卒中人群死亡率变化趋势分析及预测研究 [J ] . 中华神经外科疾病研究杂志 , 2025 , 19 ( 6 ): 74 - 80 .
程乐 , 朱才丰 , 周冰原 , 等 . 靶向炎症细胞因子治疗脑卒中的机制:开放全基因组关联研究大数据分析 [J ] . 中国组织工程研究 , 2026 , 30 ( 12 ): 3198 - 3216 .
吴丽萍 , 徐金娟 , 董国丽 . 基于血清学炎性指标构建预测缺血性脑卒中患者预后的列线图模型 [J ] . 中国微侵袭神经外科杂志 , 2024 , 28 ( 8 ): 479 - 484 .
COVENEY S , MCCABE J J , MURPHY S , et al . Dose-dependent association of inflammatory cytokines with carotid atherosclerosis in transient ischaemic attack:implications for clinical trials [J ] . Cerebrovasc Dis , 2022 , 51 ( 2 ): 178 - 187 .
LI X H , YIN F T , ZHOU X H , et al . The signaling pathways and targets of natural compounds from traditional Chinese medicine in treating ischemic stroke [J ] . Mole-cules , 2022 , 27 ( 10 ): 3099 .
中华医学会神经病学分会 , 中华医学会神经病学分会脑血管病学组 . 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022 [J ] . 中华神经科杂志 , 2022 , 55 ( 10 ): 1071 - 1110 .
周莹 , 张青松 , 万莹 , 等 . CYP2C19基因多态性指导缺血性脑卒中人群个体化用药疗效研究 [J ] . 心血管病防治知识 , 2025 , 15 ( 17 ): 14 - 17 .
杨华荣 , 郑江环 . CYP2C19基因型检测指导抗血小板治疗缺血性脑卒中的疗效及对预后的影响 [J ] . 实用临床医药杂志 , 2023 , 27 ( 22 ): 31 - 36 .
WANG A X , MENG X , TIAN X , et al . Ticagrelor aspirin vs clopidogrel aspirin in CYP2C19 loss-of-function carriers with minor stroke or TIA stratified by risk profile [J ] . Neurology , 2023 , 100 ( 5 ): e497 - e504 .
杨苗苗 , 周朝朝 , 郭敏 , 等 . 老年急诊缺血性脑卒中患者血压变异性特点及其对预后的影响 [J ] . 中华老年多器官疾病杂志 , 2025 , 24 ( 11 ): 838 - 843 .
林宏纯 , 张红 , 伍艳春 , 等 . 老年急性缺血性脑卒中患者预后不良的影响因素研究 [J ] . 神经疾病与精神卫生 , 2025 , 25 ( 6 ): 389 - 396 .
CHEN Y P , WRIGHT N , GUO Y , et al . Mortality and recurrent vascular events after first incident stroke:a 9-year community-based study of 0.5 million Chinese adults [J ] . Lancet Glob Health , 2020 , 8 ( 4 ): e580 - e590 .
刘杨 , 朱传卫 , 张青松 , 等 . CYP2C19基因多态性检测在缺血性脑卒中患者精准抗血小板治疗中的应用 [J ] . 国际检验医学杂志 , 2024 , 45 ( 10 ): 1276 - 1280 .
徐慧娜 , 董稳悦 , 赵文举 , 等 . 脑梗死恢复期病人中医证型分布及其与血小板活化状态、参数的关系 [J ] . 中西医结合心脑血管病杂志 , 2025 , 23 ( 24 ): 3707 - 3714 .
MO Y J , LU Y , GUO F , et al . Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China [J ] . Front Cardiovasc Med , 2023 , 10 : 1020593 .
SCHAEFER J H , LIESCHKE F , URBAN H , et al . Feasibility and comparability of different platelet function tests in acute stroke with or without prior antiplatelet therapy [J ] . Front Neurol , 2024 , 15 : 1361751 .
WU Y , ZHOU Y L , PAN Y S , et al . Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA stratified by age and renal function:CHANCE-2 trial substudy [J ] . Ren Fail , 2025 , 47 ( 1 ): 2526684 .
LIU F H , ZHENG X W , SHEN S W , et al . The modifying effects of hs-CRP on the association between blood pressure and stroke risk in a non-hypertensive population:a prospective cohort study [J ] . Nutr Metab Cardiovasc Dis , 2025 , 35 ( 12 ): 104230 .
DUSANOVIC PJEVIC M , VOJVODIC L , GRK M , et al . Association of IL-6 rs1800795, but not TNF-α rs1800629, and IL-1β rs16944 polymorphisms’ genotypes with reco-very of ischemic stroke patients following thrombolysis [J ] . Neurol Res , 2024 , 46 ( 2 ): 157 - 164 .
LIN L L , FAN Y C , XIE W , et al . The connection between peripheral inflammation links and functional prognosis in patients with acute ischemic stroke [J ] . Brain Res , 2025 , 1865 : 149843 .
LI F Y , XU D , HOU K , et al . Pretreatment of indobufen and aspirin and their combinations with clopidogrel or ticagrelor alleviates inflammasome mediated pyroptosis via inhibiting NF-κB/NLRP3 pathway in ischemic stroke [J ] . J Neuroimmune Pharmacol , 2021 , 16 ( 4 ): 835 - 853 .
AN X Q , LIU Z Y , ZHANG L W , et al . Co-occurrence patterns and related risk factors of ischaemic heart disease and ischaemic stroke across 203 countries and territories:a spatial correspondence and systematic analysis [J ] . Lancet Glob Health , 2025 , 13 ( 5 ): e808 - e819 .
PENG D T , PAN X Y , WEI Y H , et al . Additive interaction between CYP2C19AA gene polymorphism and Lp(a)on the prognosis of stroke patients [J ] . Am J Transl Res , 2025 , 17 ( 2 ): 1470 - 1479 .
HAJER F , MALEK A , AMANI A , et al . Beyond CYP2C19:inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients [J ] . Inflamm Res , 2025 , 74 ( 1 ): 154 .
0
Views
2
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
